FT538 in Subjects With Advanced Hematologic Malignancies
Status:
Recruiting
Trial end date:
2038-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML)
and in combination with monoclonal antibodies in multiple myeloma (MM). The study will
consist of a dose-escalation stage and an expansion stage where participants will be enrolled
into indication-specific cohorts.